Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Current Deferred Revenue (2021 - 2025)

Senti Biosciences has reported Current Deferred Revenue over the past 5 years, most recently at $43000.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue changed N/A year-over-year to $43000.0; the TTM value through Dec 2025 reached $43000.0, changed N/A, while the annual FY2025 figure was $43000.0, N/A changed from the prior year.
  • Current Deferred Revenue for Q4 2025 was $43000.0 at Senti Biosciences, down from $360000.0 in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $1.7 million in Q4 2021 and troughed at $43000.0 in Q4 2025.
  • A 5-year average of $627846.2 and a median of $639000.0 in 2024 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: tumbled 80.31% in 2023 and later surged 386.59% in 2024.
  • Year by year, Current Deferred Revenue stood at $1.7 million in 2021, then plummeted by 51.75% to $799000.0 in 2022, then grew by 23.78% to $989000.0 in 2023, then tumbled by 35.39% to $639000.0 in 2024, then crashed by 93.27% to $43000.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for SNTI at $43000.0 in Q4 2025, $360000.0 in Q2 2025, and $513000.0 in Q1 2025.